Lyell Immunopharma, Inc. (LYEL) Stock Forecast Nov. 9, 2026
Analysis updated on Nov. 9, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Lyell Immunopharma, Inc. (LYEL) stock forecast summary
Our AI scores Lyell Immunopharma, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Lyell Immunopharma, Inc. is a small-cap company with a market capitalization of $364M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its Net Margin of -1701066.7% is the lowest of the 36 peers that report one.
For LYEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 14.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +6.4%, buy ≥ +4.3%, sell < +2.2%, strong sell < +0.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-09 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LYEL included.
LYEL price chart and AI forecast
How LYEL ranks among 4224 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Lyell Immunopharma, Inc. (LYEL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | LYEL | Rank |
|---|---|---|
| Market Cap | $364M | 60/60 |
| P/B Ratio | 1.89x | 41/43 |
| EPS | $-12.32 | – |
| Book Value/Share | $7.86 | – |
| Revenue/Share | $0.00 | – |
| FCF/Share | $-5.71 | – |
Profitability & Margins
| Metric | LYEL | Rank |
|---|---|---|
| ROE | -132.4% | 34/39 |
| ROA | -93.2% | 41/43 |
| ROIC | -117.6% | 43/45 |
| Operating Margin | -1783580.0% | 39/39 |
| Net Margin | -1701066.7% | 36/36 |
| EBT Margin | -1783580.0% | 46/46 |
Financial Health
| Metric | LYEL | Rank |
|---|---|---|
| Current Ratio | 4.02x | 18/58 |
| D/E Ratio | 0.42x | 32/48 |
| Financial Leverage | 1.42x | 31/48 |
| Working Capital | $140M | 51/58 |
Cash Flow
| Metric | LYEL | Rank |
|---|---|---|
| Operating Cash Flow | -$139M | 45/59 |
| Free Cash Flow | -$140M | 38/50 |
| Capital Spending | -$710K | 8/50 |
| FCF/Sales | -933100.0% | 42/42 |
| CapEx/Sales | 4766.7% | 1/42 |
Operational Efficiency
| Metric | LYEL | Rank |
|---|---|---|
| Asset Turnover | 0.00x | 38/39 |
| Fixed Assets Turnover | 0.0x | 41/41 |
Income Statement
| Metric | LYEL | Rank |
|---|---|---|
| Total Revenue | $10K | 46/46 |
| Operating Income | -$268M | 40/51 |
| Net Income | -$255M | 35/47 |
| R&D Expense | $169M | 51/58 |
Dividend & Shareholder Information
| Metric | LYEL | Rank |
|---|---|---|
| Shares Outstanding | 25M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $186M | 68.0% of assets |
| Cash & Short-term Investments | $92M | 33.6% of assets |
| Total Liabilities | $81M | 29.6% of assets |
| Short-term Debt | $42M | 15.4% of assets |
LYEL quarterly financials and insider trading
Lyell Immunopharma, Inc. (LYEL) industry peers
Companies classified under the same SEC industry code as Lyell Immunopharma, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| LYEL Lyell Immunopharma, Inc. | $364M | |
| LLY Eli Lilly & Co | $1.27T | |
| JNJ Johnson & Johnson | $664.95B | |
| ABBV Abbvie Inc. | $518.30B | |
| MRK Merck & Co., Inc. | $362.01B | |
| NVS Novartis Ag | $310.17B | |
| AZN Astrazeneca Plc | $293.55B | |
| ABT Abbott Laboratories | $192.16B | |
| NVO Novo Nordisk A S | $179.14B | |
| PFE Pfizer Inc | $167.51B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $138.67B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $115.97B | |
| GSK Gsk Plc | $103.98B | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.66B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | |
| ONC Beone Medicines Ltd. | $46.26B | |
| GMAB Genmab A/S | $35.90B | |
| ZTS Zoetis Inc. | $32.81B | |
| RPRX Royalty Pharma Plc | $28.82B | |
| ROIV Roivant Sciences Ltd. | $28.08B | |
| INSM Insmed Inc | $25.10B | |
| UTHR United Therapeutics Corp | $24.11B | |
| VTRS Viatris Inc | $22.87B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | |
| ASND Ascendis Pharma A/S | $17.07B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.24B | |
| BBIO Bridgebio Pharma, Inc. | $15.18B | |
| ELAN Elanco Animal Health Inc | $13.41B | |
| SMMT Summit Therapeutics Inc. | $13.03B | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | |
| BMRN Biomarin Pharmaceutical Inc | $11.07B | |
| TGTX Tg Therapeutics, Inc. | $9.49B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.23B | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | |
| CORT Corcept Therapeutics Inc | $8.11B | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | |
| ALKS Alkermes Plc. | $7.75B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | |
| CYTK Cytokinetics Inc | $7.67B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.37B | |
| AXSM Axsome Therapeutics, Inc. | $7.02B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.96B | |
| ABVX Abivax S.A. | $6.83B | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.80B | |
| BLTE Belite Bio, Inc | $6.20B | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.09B | |
| COGT Cogent Biosciences, Inc. | $5.82B | |
| MANE Veradermics, Inc | $5.80B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | |
| ERAS Erasca, Inc. | $5.46B | |
| EWTX Edgewise Therapeutics, Inc. | $5.29B | |
| IONS Ionis Pharmaceuticals Inc | $5.15B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $5.03B | |
| TVTX Travere Therapeutics, Inc. | $4.44B |
Where LYEL sits on the market map
Lyell Immunopharma, Inc. (LYEL) stock news
Loading...
Lyell Immunopharma, Inc. (LYEL) stock forecast FAQ
What is the Lyell Immunopharma, Inc. (LYEL) stock forecast?
Our AI scores Lyell Immunopharma, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Lyell Immunopharma, Inc. stock predictions?
For LYEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 14.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Lyell Immunopharma, Inc. forecasts updated?
Lyell Immunopharma, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 9, 2026.
Which companies are Lyell Immunopharma, Inc.'s industry peers?
60 issuers in our coverage, LYEL included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.